Hughes J M, Seale J P, Temple D M
Eur J Pharmacol. 1983 Nov 25;95(3-4):239-45. doi: 10.1016/0014-2999(83)90640-4.
The inhibitory effects of fenoterol, a beta 2-adrenoceptor agonist, on the release of SRS-A leukotrienes and histamine from chopped human lung tissue were measured and selective beta-adrenoceptor antagonists used to investigate the nature of the receptors involved. Fenoterol 0.01-1.0 microM inhibited the antigen-induced release of SRS-A and histamine, but not the release induced by the calcium ionophore A23187. Propranolol 0.1 and 1.0 microM and butoxamine 10 and 100 microM significantly antagonized the effects of fenoterol 0.1 microM on SRS-A and histamine at concentrations which affect (beta 2-adrenoceptors, while atenolol 0.1 to 10 microM showed no antagonism at concentrations which affect beta 1-adrenoceptors. These results suggest that adrenoceptors in human lung which modulate the immunological release of SRS-A leukotrienes are of the beta 2-subtype as for histamine release.
测定了β2 -肾上腺素能受体激动剂非诺特罗对切碎的人肺组织中SRS - A白三烯和组胺释放的抑制作用,并使用选择性β -肾上腺素能拮抗剂来研究相关受体的性质。0.01 - 1.0微摩尔的非诺特罗抑制抗原诱导的SRS - A和组胺释放,但不抑制钙离子载体A23187诱导的释放。0.1和1.0微摩尔的普萘洛尔以及10和100微摩尔的丁氧胺在影响β2 -肾上腺素能受体的浓度下显著拮抗0.1微摩尔非诺特罗对SRS - A和组胺的作用,而0.1至10微摩尔的阿替洛尔在影响β1 -肾上腺素能受体的浓度下未显示出拮抗作用。这些结果表明,调节SRS - A白三烯免疫释放的人肺中的肾上腺素能受体与组胺释放一样,属于β2亚型。